Delving into the Latest Updates on Anti-CD19 CAR NK cells(Nanjing Enricnk Biotech) with Synapse

Overview

Basic Info

Drug Type

CAR-NK

Synonyms

Target

CD19

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, Natural killer cell replacements

Therapeutic Areas

Immune System DiseasesNervous System DiseasesHemic and Lymphatic Diseases+ [3]

Active Indication

Autoimmune DiseasesAntisynthetase SyndromeRheumatoid Arthritis+ [3]

Inactive Indication-

Originator Organization

Nanjing Enrui Kenuo Biotechnology Co., Ltd.

Active Organization

Nanjing Enrui Kenuo Biotechnology Co., Ltd.Third Affiliated Hospital of Nanjing Medical University

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

A single-center, open-label dose-escalation design to evaluate the safety and efficacy of 3 infusions of anti CD19 CAR NK cells (KN5501), as well as the expansion and persistence of KN5501 in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA); To evaluate the ability of KN5501 to clear CD19-positive B cells in patients to determine the feasibility of KN5501 for the treatment of refractory ASyS and or RA.

Start Date20 Oct 2024

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

[+1]

NCT06337474 / Not yet recruitingEarly Phase 1IIT

An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cell Injections for the Treatment of Refractory Primary Immune Thrombocytopenia

A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19 CAR NK cells (KN5501) in patients with refractory immune thrombocytopenia. 9 patients are planned to be enrolled in the dose-escalation trial (9×10^9 cells, 13.5×10^9 cells). The primary objective of the study is to evaluation of the safety and feasibility of KN5501 for the treatment of relapsed/refractory B-cell related autoimmune diseases. The secondary objective is to evaluate evaluation of KN5501 for the treatment of refractory immune thrombocytopenia. The exploratory objective is to evaluate expansion, persistence and ability to deplete CD19 positive B cells of KN5501 in patients with refractory immune thrombocytopenia.

Start Date30 Aug 2024

Sponsor / Collaborator

Changshu No. 2 People's Hospital

[+1]

NCT06464679 / RecruitingPhase 1IIT

An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19 CAR NK cells in patients with autoimmune diseases. 36-72 patients are planned to be enrolled in the dose-escalation trial. The primary objective of the study was to evaluate the safety and feasibility of CD19 CAR-NK cells for the treatment of patients with autoimmune diseases. The secondary objective is to evaluate the efficacy of CD19 CAR-NK cells in patients with autoimmune diseases.

Start Date27 Jun 2024

Sponsor / Collaborator

Changhai Hospital of Shanghai

[+1]

100 Clinical Results associated with Anti-CD19 CAR NK cells(Nanjing Enricnk Biotech)

Login to view more data

100 Translational Medicine associated with Anti-CD19 CAR NK cells(Nanjing Enricnk Biotech)

Login to view more data

100 Patents (Medical) associated with Anti-CD19 CAR NK cells(Nanjing Enricnk Biotech)

Login to view more data

6

Literatures (Medical) associated with Anti-CD19 CAR NK cells(Nanjing Enricnk Biotech)

30 Apr 2024·PNAS Nexus

Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors

Article

Author: Balligand, Thomas ; Verhaar, Elisha R ; Ploegh, Hidde L ; Knoflook, Anouk ; van Keizerswaard, Willemijn J C

AbstractThe glycoproteins MICA and MICB are upregulated on the surface of cells undergoing stress, for instance due to (viral) infection or malignant transformation. MICA/B are the ligands for the activating receptor NKG2D, found on cytotoxic immune cells like NK cells, CD8+ T cells, and γδ T cells. Upon engagement of NKG2D, these cells are activated to eradicate the MICA/B-positive targets, assisted by the secretion of cytokines. Nanobodies, or VHHs, are derived from the variable regions of camelid heavy-chain only immunoglobulins. Nanobodies are characterized by their small size, ease of production, stability, and specificity of recognition. We generated nanobodies that recognize membrane-bound MICA with high affinity. Here, we use these nanobodies as building blocks for a chimeric antigen receptor (CAR) to establish VHH-based CAR NK cells. These anti-MICA nanobody-based CAR NK cells recognize and selectively kill MICA-positive tumor cells in vitro and in vivo. We track localization of the VHH-based CAR NK cells to MICA-positive lung metastases by immuno-positron emission tomography imaging.

01 Nov 2020·Bundesgesundheitsblatt - Gesundheitsforschung - GesundheitsschutzQ4 · MEDICINE

Chimäre Antigenrezeptoren (CARs) in der Onkologie: eine Übersicht zu klinischer Anwendung und neuen Entwicklungen

Q4 · MEDICINE

Review

Author: Buchholz, Christian J ; Hartmann, Jessica ; Michels, Alexander

08 Sep 2020·Blood AdvancesQ2 · MEDICINE

Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy

Q2 · MEDICINE

Article

Author: Blish, Catherine A. ; Waymouth, Robert M. ; Haabeth, Ole A. W. ; Wender, Paul A. ; Vergara, Rosemary ; Weidenbacher, Nancy Lynn-Benner ; Levy, Ronald ; Wilk, Aaron J.

AbstractChimeric antigen receptor (CAR) natural killer (NK) cells are an emerging cell therapy with promising results in oncology trials. However, primary human NK cells are difficult to transfect, hampering both mechanistic studies and clinical applications of NK cells. Currently, NK cell CAR modification relies on viral vectors or cell activation. The former raises cost and tolerability issues, while the latter alters NK cell biology. Here, we report that readily synthesized and inexpensive nonviral charge-altering releasable transporters (CARTs) efficiently transfect primary human NK cells with messenger RNA without relying on NK cell activation. Compared with electroporation, CARTs transfect NK cells more efficiently, better preserve cell viability, and cause minimal reconfiguration of NK cell phenotype and function. We use CARTs to generate cytotoxic primary anti-CD19 CAR NK cells, demonstrating this technology can drive clinical applications of NK cells. To our knowledge, CARTs represent the first efficacious transfection technique for resting primary human NK cells that preserves NK cell phenotype and can enable new biological discoveries and therapeutic applications of this understudied lymphocyte subset.

100 Deals associated with Anti-CD19 CAR NK cells(Nanjing Enricnk Biotech)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Antisynthetase Syndrome	Phase 1	-	Nanjing Enrui Kenuo Biotechnology Co., Ltd.	20 Oct 2024
Antisynthetase Syndrome	Phase 1	-	Third Affiliated Hospital of Nanjing Medical University	20 Oct 2024
Rheumatoid Arthritis	Phase 1	-	Nanjing Enrui Kenuo Biotechnology Co., Ltd.	20 Oct 2024
Rheumatoid Arthritis	Phase 1	-	Third Affiliated Hospital of Nanjing Medical University	20 Oct 2024
Alloimmune thrombocytopenia	Phase 1	-	Nanjing Enrui Kenuo Biotechnology Co., Ltd.	30 Aug 2024
Purpura, Thrombocytopenic, Idiopathic	Phase 1	-	Nanjing Enrui Kenuo Biotechnology Co., Ltd.	30 Aug 2024
Autoimmune Diseases	Phase 1	CN	Nanjing Enrui Kenuo Biotechnology Co., Ltd.	27 Jun 2024
Immune-mediated renal disorder	Phase 1	CN	Nanjing Enrui Kenuo Biotechnology Co., Ltd.	21 Jun 2024